tirzepatide adolescent obesity trial A 3-year study of in participants with and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 Tirzepatide for Patients with Obesity

Blood pressure responds dramatically to weight loss in most people

doi: 10.3389/fcvm.2025.1731127 Received 23 October 2025 Revised 15 November 2025 Accepted 28 November 2025 Published 15 December 2025 Volume 12 - 2025 Edited by Manfredi Tesauro, University of Rome Tor Vergata, Italy Reviewed by Angelo Maria Patti, University of Palermo, Italy Antonio Maria Labate, ASST Franciacorta, Italy Updates Copyright 2025 Tan, Yin and Lu

The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed

Ask us what is right for you

Always consult a qualified healthcare professional before starting any new skin or wellness treatment.

These are not a validated dose ladder: the amounts shown are community / vendor research-use conventions [12] and an animal-derived patent figure [4] , not clinical doses